Indaptus Therapeutics (INDP) Income from Continuing Operations (2020 - 2026)
Indaptus Therapeutics (INDP) posted quarterly Income from Continuing Operations of 2217864.0 for Q1 2026, up 51.77% year-over-year from 1461321.92 in Q1 2025, and up 72.89% quarter-over-quarter from 8179704.0 in Q4 2025.
Indaptus Therapeutics (INDP) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Indaptus Therapeutics' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 2217864.0 for Q1 2026.
- In Q1 2026, Income from Continuing Operations rose 51.77% year-over-year to 2217864.0; the TTM figure through Mar 2026 stood at 18311504.0 (down 11.19% YoY), while the FY2025 annual figure was 80571230.0, down 11.42% from the prior year.
- Income from Continuing Operations for Q1 2026 stood at 2217864.0, up from 8179704.0 in the prior quarter.
- The five-year high for Income from Continuing Operations was 2217864.0 in Q1 2026, with the low at 8179704.0 in Q4 2025.
- The 5-year median for Income from Continuing Operations is 4197376.0 (2024), against an average of 4175868.0.
- The sharpest annual moves came in 2025 and 2026: Income from Continuing Operations plunged 94.88% in 2025, then surged 51.77% in 2026.
- Indaptus Therapeutics' Income from Continuing Operations stood at 3928030.0 in 2022, then decreased by 7.04% to 4204740.0 in 2023, then increased by 0.18% to 4197376.0 in 2024, then slumped by 94.88% to 8179704.0 in 2025, then soared by 72.89% to 2217864.0 in 2026.
- Business Quant data shows INDP's Income from Continuing Operations at 2217864.0 in Q1 2026, 8179704.0 in Q4 2025, and 2657173.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Indaptus Therapeutics | 146.91 Mn | 135.35 Mn | - | -1.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -1.84 Mn |
| Mar 31, 2026 | -2.22 Mn |
| Dec 31, 2025 | -8.18 Mn |
| Sep 30, 2025 | -2.66 Mn |
| Jun 30, 2025 | -5.26 Mn |
| Mar 31, 2025 | -4.60 Mn |
| Dec 31, 2024 | -4.20 Mn |
| Sep 30, 2024 | -3.25 Mn |
| Jun 30, 2024 | -4.42 Mn |
| Mar 31, 2024 | -4.36 Mn |
| Dec 31, 2023 | -4.20 Mn |
| Sep 30, 2023 | -4.80 Mn |
| Jun 30, 2023 | -3.62 Mn |
| Mar 31, 2023 | -4.27 Mn |
| Dec 31, 2022 | -3.93 Mn |
| Sep 30, 2022 | -3.51 Mn |
| Jun 30, 2022 | -4.02 Mn |
| Mar 31, 2022 | -3.51 Mn |
| Dec 31, 2021 | -3.24 Mn |
| Sep 30, 2021 | -4.39 Mn |